Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 2/20 | 0.47 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | GLI1 | P08151 | 1/20 | 0.42 |
| ▸ | GLI2 | P10070 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5354570 | 0.91 | FDFT1 (0.57) | FDFT1NQO2NAMPTIDO1GLI1 | |
| SCHEMBL9985225 | 0.91 | NQO2 (0.52) | NQO2POLBNAMPTKDM4EIDO1 | |
| SCHEMBL21089804 | 0.87 | NQO2 (0.49) | NQO2POLBNAMPTKDM4EIDO1 | |
| SCHEMBL6203942 | 0.87 | FDFT1 (0.47) | FDFT1NQO2POLBNAMPTKDM4E | |
| SCHEMBL21090363 | 0.86 | CYP4F2 (0.49) | FDFT1NQO2CA2CA1 | |
| SCHEMBL6204579 | 0.86 | MTNR1A (0.58) | POLBCA2CA1MTNR1AMTNR1B | |
| SCHEMBL6202190 | 0.84 | PLAAT3 (0.48) | FDFT1NQO2POLBNAMPTKDM4E | |
| SCHEMBL17974300 | 0.84 | CA12 (0.54) | POLBIDO1CA2CA1MTNR1A | |
| SCHEMBL21089840 | 0.82 | CA12 (0.55) | IDO1CA2CA1 | |
| SCHEMBL29828661 | 0.82 | MTNR1A (0.48) | NQO2POLBNAMPTCA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577383-B2 | Macrocyclic inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190177340-A1 | MACROCYCLIC INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177340-A1 | MACROCYCLIC INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | FDFT1 907/4885NQO2 933/4885POLB 804/4885 |
| US-10577383-B2 | Macrocyclic inhibitors of myeloperoxidase | EPX, MPO, SERPINB1 | FDFT1 907/4885NQO2 933/4885POLB 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.